Calamos Advisors LLC Lowers Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Calamos Advisors LLC cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,623 shares of the medical research company’s stock after selling 23,327 shares during the period. Calamos Advisors LLC’s holdings in Thermo Fisher Scientific were worth $76,234,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. WCM Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares in the last quarter. Phoenix Holdings Ltd. raised its position in shares of Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after buying an additional 1,654 shares during the last quarter. DMC Group LLC raised its position in shares of Thermo Fisher Scientific by 16.5% in the third quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock valued at $300,000 after buying an additional 84 shares during the last quarter. S. R. Schill & Associates raised its position in shares of Thermo Fisher Scientific by 106.3% in the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after buying an additional 792 shares during the last quarter. Finally, Check Capital Management Inc. CA acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $219,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 1.0 %

Thermo Fisher Scientific stock traded down $5.73 during trading on Thursday, reaching $541.52. The stock had a trading volume of 2,075,756 shares, compared to its average volume of 1,547,350. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The business has a 50 day moving average price of $571.57 and a 200 day moving average price of $527.01. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The stock has a market cap of $206.70 billion, a PE ratio of 34.94, a P/E/G ratio of 2.33 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter in the previous year, the firm earned $5.40 earnings per share. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Analyst Ratings Changes

TMO has been the subject of several recent analyst reports. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. HSBC raised their price objective on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the transaction, the chief executive officer now directly owns 43,608 shares of the company’s stock, valued at approximately $24,011,436.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.